Gretchen Kimmick, MD, MS

Duke University Medical Center, Durham, NC

Pavankumar Tandra, MD

University of Nebraska Medical Center, Omaha, NE

Accredited by

American Society of Clinical Oncology

Course Description

After participating in this activity, learners will be better able to:
- Recognize the importance of upfront (neoadjuvant) HER2 directed therapy in early stage HER2 positive breast cancer.
- Identify the indications for upfront surgery and adjuvant HER2 directed therapy.
- Evaluate the impact of pathologic response at surgery on post-operative treatment for non-metastatic, HER2-positive breast cancer.

Activity Details

Credit Types:CME / MOC / CE
Credit Amount:1.50 Credits
Release Date:2019-May-31
Expiration Date:2021-May-31
Estimated Time for Completion:1 hour and 30 minutes
Registration Required:Yes

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.